Press Release

  • Press Release
  • No Likes

ABVC BioPharma Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business Update
ABVC BioPharma Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business Update 150 150 Press Release

FREMONT, CA, March 14, 2024 ABVC BioPharma Inc, a biotechnology company specializing in botanically based solutions that deliver high efficacy and low toxicity to improve health outcomes, announced its 2023 annual financial and operating results.…

read more
  • Press Release
  • No Likes

ABVC’s New Horizon for Oncology and Hematology Aims at Cancer Market of Several Hundred Billion Dollars
ABVC’s New Horizon for Oncology and Hematology Aims at Cancer Market of Several Hundred Billion Dollars 150 150 Press Release

FREMONT, CA, Feb. 27, 2024 ABVC BioPharma Inc. (NASDAQ: ABVC) (“Company”), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, today provided an update on its development of combination…

read more
  • Press Release
  • No Likes

ABVC BioPharma Executes a Definitive Agreement to Receive License Fees of $3M and Royalties of 2% on Future Revenues
ABVC BioPharma Executes a Definitive Agreement to Receive License Fees of $3M and Royalties of 2% on Future Revenues 150 150 Press Release

FREMONT, CA, Feb. 15, 2024 ABVC BioPharma Inc, (NASDAQ: ABVC) (“Company”), a clinical-stage biopharmaceutical company developing therapeutic solutions in Oncology/Hematology, Neurology, and Ophthalmology, announced today that it signed a definitive agreement to license certain of…

read more
  • Press Release
  • No Likes

ABVC BioPharma Receives Australian Patent, Valid Until 2040, for Its Treatment of Major Depressive Disorder (MDD)
ABVC BioPharma Receives Australian Patent, Valid Until 2040, for Its Treatment of Major Depressive Disorder (MDD) 150 150 Press Release

FREMONT, CA , Feb. 12, 2024 ABVC BioPharma Inc., a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, neurology, and oncology/hematology, announced today that it received an Australian patent, valid until 2040, Application No. 2021314052,…

read more
  • Press Release
  • No Likes

ABVC Acquires $2.96 Million Worth of Land in Asia with Stocks Priced at $3.50 per Share
ABVC Acquires $2.96 Million Worth of Land in Asia with Stocks Priced at $3.50 per Share 150 150 Press Release

FREMONT, CA, Feb. 08, 2024 ABVC BioPharma Inc, a clinical-stage biopharmaceutical company developing therapeutic solutions in Oncology/Hematology, Neurology, and Ophthalmology, announced today that it signed a definitive agreement to acquire real estate in Taoyuan City,…

read more
  • Press Release
  • No Likes

ABVC BioPharma and its Subsidiary Receive $460M From AiBtl BioPharma as the First Milestone Payment of Global Licensing Fees
ABVC BioPharma and its Subsidiary Receive $460M From AiBtl BioPharma as the First Milestone Payment of Global Licensing Fees 150 150 Press Release

FREMONT, CA , Jan. 03, 2024 and its subsidiary BioLite, Inc. (“Company”), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, announced today that the Company and its subsidiary…

read more
  • Press Release
  • No Likes

ABVC BioPharma Announces Completion of Subject Treatment for Interim Analysis on ADHD Phase IIb Clinical Study
ABVC BioPharma Announces Completion of Subject Treatment for Interim Analysis on ADHD Phase IIb Clinical Study 150 150 Press Release

FREMONT, CA, Dec. 07, 2023 (NASDAQ: ABVC) (“Company”), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced an update on the Company’s eight-week long ADHD Phase II part II clinical…

read more
  • Press Release
  • No Likes

ABVC BioPharma Enters Definitive Agreement with Licensing Income Worth $467M and Royalties Up to $200M
ABVC BioPharma Enters Definitive Agreement with Licensing Income Worth $467M and Royalties Up to $200M 150 150 Press Release

FREMONT, CA, Nov. 16, 2023 (NASDAQ: ABVC) (“Company”), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, announced today that it entered into a global licensing definitive agreement with AiBtl…

read more
  • Press Release
  • No Likes

ABVC BioPharma Reports Third Quarter 2023 Financial and Operational Results
ABVC BioPharma Reports Third Quarter 2023 Financial and Operational Results 150 150 Press Release

FREMONT, CA, Nov. 15, 2023 (NASDAQ: ABVC) (“Company”): Today, a biotechnology company specializing in botanically based solutions that deliver high efficacy and low toxicity to improve health outcomes announced its financial and operating results for…

read more
  • Press Release
  • No Likes

ABVC BioPharma Entered Into a Term Sheet to License Global Rights of CNS Drugs with the Indications of MDD and ADHD to AiBtl BioPharma at the Valuation of $667 Million
ABVC BioPharma Entered Into a Term Sheet to License Global Rights of CNS Drugs with the Indications of MDD and ADHD to AiBtl BioPharma at the Valuation of $667 Million 150 150 Press Release

FREMONT, CA, Oct. 26, 2023 — (NASDAQ: ABVC) (“Company”), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, announced today that it entered into a legal binding term sheet…

read more

BACKGROUND

Leadership Team

MANAGEMENT
ADVISORY

NASDAQ: ABVC

Latest News

ABVC NEWSROOM

THERAPEUTIC FOCUS

Retinal Vitrectomy

Vitargus® – ABV-1701
Contact ABVC & Stay Informed

Contact ABVC BioPharma

SOCIAL MEDIA

Facebook

LinkedIn

TELEPHONE

+1 845-291-1291

EMAIL

info@abvcpharma.com

44370 Old Warm Springs Boulevard
Fremont, California 94538 USA
CONTACT FORM

Copyright ©2023 ABVC BioPharma, Inc. All Rights Reserved.

   

Enter your
search terms here.